Goran A. Ando
Pharmaceuticals
Molecular Partners AG
Germany
Biography
Goran A. Ando, M.D. is Member of Board of the Directors of Molecular Partners Ltd. He is Chairman of the Board of Directors of Novo Nordisk A/S. Dr. Ando was Chief Executive Officer of Celltech Group plc, the United Kingdom, until 2004. He joined Celltech from Pharmacia, now Pfizer, the United States, where he was Executive Vice President and President of R&D with additional responsibilities for Manufacturing, Information Technology, Business Development and Mergers & Acquistions (M&A) from 1995 to 2003. From 1989 to 1995, he was Medical Director, moving to deputy R&D director and then R&D Director of Glaxo Group, the United Kingdom. He was also a Member of the Glaxo Group Executive Committee. He is a founding fellow of the American College of Rheumatology in the United States. Dr. Ando serves as Chairman of the Board of Novexel SA, France, as Vice Chairman of the Board of S*Bio Pte Ltd., Singapore, and as a Board Member of Novo A/S, Denmark, Bio*One Capital Pte Ltd., Singapore, NicOx SA, France, EUSA Pharma, the United Kingdom, CBio Ltd., Australia, and Albea Pharmaceuticals AG, Switzerland. Dr Ando also serves as a Senior Advisor to Essex Woodlands Health Ventures Ltd., the United Kingdom and is Chairman of the Scientific Advisory Board, Southwest Michigan First, the United States.
Research Interest
Pharmaceuticals
